SYRS - サイロス・ファ―マシュ―ティカルズ （Syros Pharmaceuticals Inc.）

https://www.investing.com/news/assorted/syros-pharmaceuticals-presents-data-from-phase-11b-clinical-trial-of-sy5609-432SI-3091409

The following slide deck was published by Syros Pharmaceuticals, Inc.

https://www.investing.com/news/pro/syros-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3079550

Syros Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SYRS) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ETCompany ParticipantsKaren Hunady - Director, Investor Relations and Corporate…

Companies Reporting Before The Bell • Nomad Foods (NYSE: NOMD ) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million. • Banco Latinoamericano (NYSE: BLX ) is likely to report quarterly earnings at $0.42 per share on revenue of $263.98 million. • Beauty Health (NASDAQ: SKIN ) is likely to report quarterly loss at $0.02 per share on revenue of $90.37 million. • Vishay Intertechnology (NYSE: VSH ) is projected to report quarterly earnings at $0.55 per share on revenue of $845.80 million. • Bragg Gaming Group (NASDAQ: BRAG ) is estimated to report quarterly loss at $0.05 per share on revenue of $32.00 million. • Ballard Power Systems (NASDAQ: BLDP ) is projected to report quarterly loss at $0.13 per share on revenue of $24.08 million. • ProFrac Holding (NASDAQ: ACDC ) is estimated to report quarterly earnings at $0.80 per share on revenue of $893.04 million. • Roblox (NYSE: RBLX ) is projected to report quarterly loss at $0.40 per share on revenue of $765.

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the live conference call,

DelveInsight''s "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and

Syros Pharmaceuticals (SYRS) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million.

Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL ) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in pre-market trading. Truist Securities boosted the price target for Broadcom Inc. (NASDAQ: AVGO ) from $659 to $700. Truist Securities analyst William Stein maintained a Buy rating on the stock. Broadcom shares rose 0.9% to close at $598.65 on Thursday. Raymond James raised the price target for Integral Ad Science Holding Corp. (NASDAQ: IAS ) from $12 to $17. Raymond James analyst Andrew Marok maintained a Strong Buy rating. Integral Ad Science shares gained 2% to close at $10.70 on Thursday. Oppenheimer cut Syros Pharmaceuticals, Inc. (NASDAQ: … Full story available on Benzinga.com

https://www.investing.com/news/pro/syros-pharmaceuticals-pt-lowered-to-13-at-oppenheimer-432SI-3020940

DelveInsight''s "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and

Syros Pharmaceuticals (SYRS) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million.

Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL ) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in pre-market trading. Truist Securities boosted the price target for Broadcom Inc. (NASDAQ: AVGO ) from $659 to $700. Truist Securities analyst William Stein maintained a Buy rating on the stock. Broadcom shares rose 0.9% to close at $598.65 on Thursday. Raymond James raised the price target for Integral Ad Science Holding Corp. (NASDAQ: IAS ) from $12 to $17. Raymond James analyst Andrew Marok maintained a Strong Buy rating. Integral Ad Science shares gained 2% to close at $10.70 on Thursday. Oppenheimer cut Syros Pharmaceuticals, Inc. (NASDAQ: … Full story available on Benzinga.com

https://www.investing.com/news/pro/syros-pharmaceuticals-pt-lowered-to-13-at-oppenheimer-432SI-3020940

Syros Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SYRS) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ETCompany ParticipantsKaren Hunady - Director-Investor Relations & Corporate…